Spine surgeons validated clinical and economic benefits of an entirely synthetic solution in lateral lumbar fusions
"Having clinically-backed Advanced Materials Science options, from synthetic biologics to porous interbody implants, gives surgeons stronger procedural offerings across the entire spine," said
The multi-center, retrospective study consisted of 90 patients who underwent lateral lumbar interbody fusions with the combination of a synthetic bone graft substitute,
Attrax Putty is the first and only synthetic bone graft with
"I am excited to see outcomes that have been traditionally associated with BMP achieved with cost-effective biologics used in porous interbody cage technology," said
The results of this study build upon the extensive clinical evidence validating Modulus interbody technology, Attrax Putty and the broader X360 portfolio. Studies show that:
- 90 patients treated at 136 thoracolumbar levels with Modulus XLIF and Attrax Putty showed high rates of success and low rates of complications.1
- In the only Level I randomized controlled trial of a synthetic bone graft substitute in instrumented posterolateral fusion, Attrax Putty demonstrated non-inferiority to autograft.3
- When used in combination with single-position surgery, Modulus XLIF and Attrax Putty could substantially improve perioperative economics to the hospital through decreased operative time, while meeting postoperative alignment and clinical outcome goals.4-7
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
1 Malone H, Mundis Jr.,
2 Fogel G, Martin N, Lynch K, et al. Subsidence and fusion performance of a 3D-printed porous interbody cage with stress-optimized body lattice and microporous endplates - a comprehensive mechanical and biological analysis. Spine J 2022;22:1028-37.
3 Lehr AM, Oner FC, Delawi D, et al. Efficacy of a Standalone microporous ceramic vs. autograft in instrumented posterolateral spinal fusion; a multicenter, randomized, intra-patient controlled, non-inferiority trial. Spine 2020;45(14):944-51.
4 Blizzard DJ, Thomas JA. MIS Single-position lateral and oblique lateral lumbar interbody fusion and bilateral pedicle screw fixation: feasibility and perioperative results. Spine 2017 Jul 12. [Epub ahead of print]
5 Rhee JW, Petteys RJ, Anaizi AN, et al. Prospective evaluation of 1-year outcomes in single-level percutaneous lumbar trans facet screw fixation in the lateral decubitus position following lateral trans psoas interbody fusion.
6 Thomas JA. Single-position lateral lumbar interbody fusion and percutaneous pedicle screw fixation allows for adequate correction of spinal sagittal imbalance. Paper presented at
7 Voyadzis JM, Anaizi AN. Minimally invasive lumbar trans facet screw fixation in the lateral decubitus position after extreme lateral interbody fusion: a technique and feasibility study. J Spinal Disord Tech 2013;26(2):98-106.
View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-study-validates-nuvasive-porous-interbody-implant-and-synthetic-bone-graft-substitute-as-cost-effective-solution-for-lateral-lumbar-interbody-fusions-301592968.html
CONTACTS: Investor contact: Juliet C. Cunningham, NuVasive, Inc., 858-210-2129, email@example.com; Media contact: Melanie Ordoñez, NuVasive, Inc., 858-722-3899, firstname.lastname@example.org